Quantcast
Last updated on April 17, 2014 at 10:07 EDT

Latest American Association for Cancer Research Stories

2011-12-06 08:00:00

New Star-Studded SU2C Print Public Service Announcement LOS ANGELES, Dec. 6, 2011 /PRNewswire-USNewswire/ -- Stand Up To Cancer (SU2C) is proud to announce a new public service announcement (PSA) featuring the stellar ensemble cast of the holiday romantic comedy NEW YEAR'S EVE from director Garry Marshall (Pretty Woman, Valentine's Day), that will appear in national and regional publications during the month of December. The new SU2C print PSA campaign asks the public to join the cast of...

2011-11-29 11:58:00

MANHATTAN BEACH, Calif., Nov. 29, 2011 /PRNewswire/ -- A $1.4 million gift from The Daniel and Janet Mordecai Foundation will provide crucial funding for the Pancreatic Cancer Action Network's 2012 Research Grants Program, enabling the organization to support the investigations of a new class of early career scientists. Daniel Mordecai died in 2002 from pancreatic cancer, the fourth leading cause of cancer death in the United States. (Logo: <font size="2"...

2011-11-25 06:49:31

(Ivanhoe Newswire) — Coffee could help reduce your risk of developing endometrial cancer. The study by the American Association for Cancer Research showed that long term coffee consumption may be associated with a reduced risk for endometrial cancer. "Coffee has already been shown to be protective against diabetes due to its effect on insulin. So we hypothesized that we'd see a reduction in some cancers as well," Edward Giovannucci, M.D., Sc.D., professor of nutrition and...

2011-11-22 08:15:00

Application now available online WASHINGTON, Nov. 22, 2011 /PRNewswire-USNewswire/ -- LUNGevity issued their 2012 Career Development Award for Translational Research RFA today. It's available on the LUNGevity website at www.lungevity.org/research and is also posted on the proposalCENTRAL website. LUNGevity's Career Development Awards for Translational Research program was created with one goal: to identify a cohort of future research leaders who will keep the field of...

2011-11-17 10:20:06

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease. Mark Rubin, M.D., professor of pathology and laboratory medicine at Weill Cornell Medical College, said although fewer than 2 percent of men with prostate cancer present with neuroendocrine prostate cancer, the more common prostate adenocarcinoma can also evolve into...

2011-11-15 21:15:41

Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011. Heinz-Herbert Fiebig, M.D., Ph.D., associate professor of medical oncology at the University of Freiburg in Germany, presented data from 25...

2011-11-14 22:26:23

Scientists are another step closer to understanding what drives tumor metastasis, as laboratory models suggest there are factors inside tumors that can slow their own growth. In a recent issue of Cancer Research, a journal of the American Association for Cancer Research, Raúl A. Ruggiero, Ph.D., a biological researcher at the division of experimental medicine at the National Academy of Medicine in Buenos Aires, Argentina, described this novel mechanism. Ruggiero and...

2011-11-14 15:24:49

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma. The studies, presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011, further elucidated...

2011-11-14 15:21:51

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011. "These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said...

2011-11-14 15:20:53

Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a novel antiangiogenic receptor may help patients whose cancer does not respond to existing agents. The experimental agent, PF-03446962, targets activin...